Conference Reports for NATAP

Back

ID Week 2017 Advancing Science, Improving Care October 4-8 San Diego, CA     Pharmacokinetics of Temsavir, the Active Moiety of the Prodrug Fostemsavir, in Subjects with Hepatic Impairment (10/28/17)   Pharmacokinetics of Cabotegravir in Subjects With Severe Renal Impairment (10/28/17)   Pharmacokinetics of Cabotegravir in Subjects With Moderate Hepatic Impairment (10/28/17)   HIV in the Brain - MANAGING COMORBIDITIES IN PATIENTS WITH HIV (10/16/17)   Medium Grade Proteinuria Is Not a Relevant Predictor of Chronic Kidney Disease in People Living with HIV/AIDS - Or Is It? (10/16/17)   Low Rate of Routine Proteinuria Screening among Male HIV Patients in an Urban Clinic (10/16/17)   Incidence of symptomatic CSF viral escape in HIV infected adults receiving atazanavir/ritonavir (ATV/r)-containing ART: A tertiary care cohort in western India (10/16/17)   Three-Part Strategy Boosts Extragenital STI Screening 23% in HIV Clinic - Mark Mascolini (10/13/17)   High Comfort Level With STI Self-Tests in HIV Group; Results Match Provider Tests - Mark Mascolini (10/13/17)   Primary Care Providers Have Limited Knowledge About STI Screening And HIV PrEP in Men Who have Sex with Men - Training Did Not Improve Provider Knowledge of STIs and PrEP for MSM - Mark Mascolini (10/13/17)   Three Quarters of Women in HIV Group May Have ART-Hormonal Interactions - Mark Mascolini (10/13/17)   Age, Gender, Race Predict Long-Term PrEP Adherence in Large Veterans Group - Mark Mascolini (10/13/17)   Should Guidelines Shorten Virologic Failure Cutoff for Integrase Inhibitors? - Mark Mascolini (10/13/17)   Two Thirds in South Carolina With New HIV Missed Chance to Use PrEP - "Missed Opportunities to Initiate HIV Pre-exposure Prophylaxis in South Carolina - 2013-2016"....women, Blacks, young, MSM (10/12/17)   Cancer mortality among persons with Human Immunodeficiency Virus Infection, New York City, 2001-2015 - Lung (most) & Liver Cancer, Breast Cancer, Colorectal Cancers, Non-Hodgkins Lymphoma; RISK FACTORS: low CD4, unsupressed viral load; IDU; Hispanic (10/12/17)   Implementation of Hepatitis C Elimination - John Ward, MD, CDC (10/12/17)   Risk Behavior--and Sex Partner Type--Predict PrEP Adherence in MSM - Mark Mascolini (10/12/17)   Access to Online Tools Boosts Chances of HIV Control in Large US Group - "ASSOCIATION BETWEEN PATIENT PORTAL ACCESS & VIRAL SUPPRESSION AMONG PEOPLE LIVING WITH HIV" - Mark Mascolini (10/12/17)   Similar Frequency of New HIV in US Group 45 or Older vs Younger - (10/11/17)   Prevalence of systemic hypertension among HIV-infected and HIV-uninfected young adults - Young Adults Perinatally Infected With HIV Run Higher Hypertension Risk - Mark Mascolini (10/11/17)   Effect of a multidisciplinary intervention for early ART initiation for inpatients with newly diagnosed HIV: Inpatient Program Yields Higher Linkage and ART Rates in Atlanta Hospital - Mark Mascolini (10/11/17)   Linkage and Anti-Retroviral Therapy Initiation Within 72-hours at a Ryan White-Funded FQHC in the Deep South in New Orleans - Mark Mascolini (10/11/17)   Under One Third of ID Fellows Think They Got Enough Training on ART or PrEP - Mark Mascolini (10/11/17)   48-Week Safety and Efficacy On-Treatment Analysis of Ibalizumab in Patients with Multi-Drug Resistant HIV-1 - (10/11/17)   Fatty Liver Disease in HIV: Predictors and Response to Statin Therapy - (10/11/17)   Faster Fatty Liver Progression With Statin Than Placebo in SATURN HIV Trial - Mark Mascolini (10/11/17)   Trends and Associations with PrEP Prescription among 602 NYC Ambulatory Care Practices, 2014-16...... "PrEP prescriptIon increased 976% between Q1 2014 to Q2 2016 among 602 ambulatory care practIces in NYC" - (10/11/17)   Real World Effectiveness of Ledipasvir/Sofosbuvir (LDV/SOF) for 8 Weeks in Patients Coinfected With HCV GT 1 and HIV-1 - (10/11/17)   Hepatitis C Virus Treatment Response to Ledipasvir/Sofosbuvir among patients co-infected with HIV and HCV: Real World Data in a Black Population - (10/11/17)   Glycemic Control & HbA1C Change After SVR - Mark Mascolini - (10/11/17)   Good In-Practice SVR12 With Sofosbuvir Regimens After HCV PI Failure in HIV/HCV Coinfected - Mark Mascolini - (10/11/17)   Barriers to Hepatitis C Treatment in HIV co-infected Patients in the Era of New Direct-Acting Antiviral Therapy (Philadelphia): Just Over Half With HCV/HIV at Academic Center Get DAAs for HCV - Mark Mascolini - (10/11/17)   High Asymptomatic STI Prevalence and Incidence in French MSM Starting PrEP - Mark Mascolini - (10/10/17)   Trends and Associations with PrEP Prescription among 602 NYC Ambulatory Care Practices, 2014-16......"PrEP prescriptIon increased 976% between Q1 2014 to Q2 2016 among 602 ambulatory care practIces in NYC" - (10/10/17)   Phase 3 Randomized, Controlled Trial of Switching to Fixed-Dose Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) from Boosted Protease Inhibitor-Based Regimens in Virologically Suppressed Adults: Week 48 Results - (10/10/17)   Impact of Tablet Burden and Antiretroviral Therapy (ART) Choice on Virologic Outcomes in Treatment-Naive HIV+ Individuals Attending an Inner City Clinic - (10/10/17)   Switch to Darunavir/C/FTC/TAF Noninferior to Continued PI Plus TDF/FTC - Mark Mascolini - (10/10/17)   SWORD-1 & SWORD-2: Subgroup Analysis of 48-Week Results by Age, Race and Gender - Maintenance With DTG/RPV Effective Regardless of Age, Sex, or Race - Mark Mascolini - (10/10/17)   Efficacy and Safety of Tenofovir Alafenamide vs Tenofovir Disoproxil Fumarate in HIV-Infected, Virologically Suppressed, Black and Nonblack Adults Through Week 96: Subgroup Analysis of a Randomized Switch Study - - (10/10/17)   Lack of Clinically Relevant Effect of Bictegravir on Metformin Pharmacokinetics and Pharmacodynamics - (10/10/17)   Viral Failure Among Persons Living with HIV Initiating Dolutegravir-Based vs. Other Recommended Regimens in Real-World Clinical Care Settings - (10/10/17)   Abacavir Use and Risk for Myocardial Infarction and Coronary Artery Disease: Updated Meta-analysis of Data From Clinical Trials - (10/10/17)   Selected CNS Outcomes Among a Large Sample of Patients Treated with INSTI Antiretrovirals - (10/09/17)   Real-World Experience with Higher-Than-Recommended Doses of Lamivudine in Patients with Varying Degrees of Renal Impairment - (10/09/17)   WEIGHT GAIN AFTER SWITCH FROM EFAVIRENZ-BASED TO INTEGRASE INHIBITOR-BASED REGIMENS - Atripla-to-Integrase Inhibitor Switch Tied to Weight Gain Over 18 Months - Mark Mascolini - (10/09/17)   Three Quarters of International HIV Group Worry About Long-Term Effects of ART - "Patient Experience and Views on Antiretroviral Treatment-Findings From the Positive Perspectives Study" - Mark Mascolini - (10/09/17)   SWORD-1 & SWORD-2: Subgroup Analysis of 48-Week Results by Age, Race and Gender - (10/09/17)   A Randomized Trial of Bictegravir or Dolutegravir With Emtricitabine and Tenofovir Alafenamide (F/TAF) Followed by Open-label Switch to Bictegravir/F/TAF Fixed-Dose Combination - High Virologic Response Rates With Bictegravir or Dolutegravir Plus FTC/TAF - Mark Mascolini - (10/09/17)   Efficacy and safety of switching from boosted protease inhibitors plus emtricitabine and tenofovir disoproxil fumarate regimens to single-tablet darunavir, cobicistat, emtricitabine, and tenofovir alafenamide at 48 weeks in adults with virologically suppressed HIV-1 (EMERALD): a phase 3, randomised, non-inferiority trial - (10/09/17)   Janssen Announces Pivotal Phase 3 Study Results for Investigational Darunavir-Based Single-Tablet Regimen for the Treatment of HIV-1 Infection in Adults Switching from Boosted Protease Inhibitors Plus Emtricitabine and Tenofovir Disoproxil Fumarate Regimens - (10/09/17)   Week 48 results of EMERALD: A Phase 3, randomized, non-inferiority study evaluating the efficacy and safety of switching from boosted-protease inhibitors plus emtricitabine/tenofovir disoproxil fumarate regimens to the once daily, single-tablet regimen of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in virologically-suppressed, HIV-1-infected adults - (10/09/17)   The Incidence and Risk Factors Associated with Chronic Liver Enzyme Elevation (cLEE) in HIV-Monoinfected Persons - Antiretroviral Use and Race Predict High Liver Enzymes in HIV-Monoinfected - Mark Mascolini - (10/09/17)   Echocardiography Spots Abnormalities in up to 26% of Air Force Members With Early HIV - Mark Mascolini - (10/09/17)   Low Dietary Calcium Tied to Low Bone Density With HCV But Not HIV - Mark Mascolini - (10/06/17)   Incidence of Herpes Zoster in a Large Cohort of Persons Living with HIV - Herpes Zoster Incidence Falling in HIV Group But Still at 1% in 2011-2016 - Mark Mascolini - (10/06/17)   Two Thirds of HIV Group Who Need Statins Not Getting Them - Mark Mascolini - (10/06/17)   Framingham Cardio Risk Score Twice Higher in Premenopausal Women With HIV - Mark Mascolini - (10/06/17)   Multiple Missed Chances to Prevent Heart Disease in Urban HIV Clinic - Mark Mascolini - (10/06/17)   Low Screening Rates for HBV, HCV, and Diabetes in NYC HIV Cohort - Mark Mascolini - (10/06/17)